Direct quality control of glycoengineered erythropoietin variants

Recombinant production of glycoprotein therapeutics like erythropoietin (EPO) in mammalian CHO cells rely on the heterogeneous N-glycosylation capacity of the cell. Recently, approaches for engineering the glycosylation capacities of mammalian cells for custom designed glycoforms have been developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Čaval, Tomislav, Tian, Weihua, Yang, Zhang, Clausen, Henrik, Heck, Albert J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104044/
https://www.ncbi.nlm.nih.gov/pubmed/30131559
http://dx.doi.org/10.1038/s41467-018-05536-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104044/
https://www.ncbi.nlm.nih.gov/pubmed/30131559
http://dx.doi.org/10.1038/s41467-018-05536-3

Ejemplares similares